Stifel analyst Paul Matteis maintains Hold on Alexion Pharmaceuticals (NASDAQ: ALXN).The analyst comments "This morning, ALXN reported positive data for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE